The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the
The post Circassia to buy US, China marketing rights to AIT’s AirNOvent appeared first on Pharmaceutical Business review.
Original Article: Circassia to buy US, China marketing rights to AIT’s AirNOvent